Latest News-Yisheng US Biopharmaceutical Inc. Mediaroom_Page

YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024

Pipeline makes progress towards commercialization as robust demand for YSJA rabies vaccine continue...

2023-08-16 05:00 2498

YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023

GAITHERSBURG, Md., Aug. 10, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma...

2023-08-11 04:30 4602

YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023

Total revenues increase by 36.3% year-over-year; gross margin improves to 77.7%; balance sheet rema...

2023-07-27 05:00 4140

YS Biopharma to Report Financial Results for Fiscal Year 2023 on July 26, 2023

GAITHERSBURG, Md., July 21, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma...

2023-07-22 04:30 4203

YS Biopharma to Report Financial Results for Fiscal Year 2023 on July 26, 2023

GAITHERSBURG, Md., July 22, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma...

2023-07-22 04:30 3416

YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA

GAITHERSBURG, Md., June 1, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma"...

2023-06-01 20:30 2627

YS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 2023

GAITHERSBURG, Md., May 18, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma"...

2023-05-18 20:25 3753

YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in Pakistan

GAITHERSBURG, Md., May 16, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma"...

2023-05-16 19:00 1957

YS Biopharma Announces Record Vaccine Revenues and Preliminary Financial Results for FY2023 Ended March 31, 2023

FY2023 Revenues Increased by Approximately 30% Year Over Year GAITHERSBURG, Md., April 18, 2023 /P...

2023-04-18 19:00 2230

YS Biopharma's PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Responses Compared to Inactivated COVID-19 Vaccine in Phase II Head-to-Head Clinical Study

* The trial met its primary endpoint of superior immunogenicity of PIKA COVID-19 Vaccine vs inact...

2023-03-27 18:00 1630

YS BIOPHARMA TO RING THE OPENING BELL AND DEBUT ON NASDAQ

YS Biopharma Ordinary Shares and Warrants to Trade on the Nasdaq Under Tickers "YS" and "YSBPW" ...

2023-03-17 04:30 2281

YS BIOPHARMA AND SUMMIT HEALTHCARE ANNOUNCE SHAREHOLDER APPROVAL OF BUSINESS COMBINATION

* Business Combination to deliver approximately $36 million of gross proceeds * YS Biopharma exp...

2023-03-15 04:01 3683

SUMMIT HEALTHCARE ACQUISITION CORP. AND YS BIOPHARMA ANNOUNCE EFFECTIVENESS OF REGISTRATION STATEMENT AND EXTRAORDINARY GENERAL MEETING DATE FOR PROPOSED BUSINESS COMBINATION

* Extraordinary general meeting of Summit Healthcare Acquisition Corp.'s shareholders to be held ...

2023-02-08 21:30 3049

SUMMIT HEALTHCARE ACQUISITION CORP. AND YS BIOPHARMA ANNOUNCE EFFECTIVENESS OF REGISTRATION STATEMENT AND EXTRAORDINARY GENERAL MEETING DATE FOR PROPOSED BUSINESS COMBINATION

* Extraordinary general meeting of Summit Healthcare Acquisition Corp.'s shareholders to be held ...

2023-02-08 21:30 2948

YS Biopharma Received Qualified Person Declaration for Its PIKA COVID-19 Vaccine Facility Equivalent to European Union GMP

GAITHERSBURG, Maryland, Nov. 16, 2022 /PRNewswire/ -- YS Biopharma Co., Ltd. ("YS Biopharma" or th...

2022-11-16 08:50 2234

YS Biopharma Announces US FDA Clearance Of IND Application For PIKA COVID-19 vaccine

NEW YORK, Nov. 10, 2022 /PRNewswire/ -- YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a...

2022-11-10 22:30 2631

YS BIOPHARMA TO MERGE WITH NASDAQ-LISTED SUMMIT HEALTHCARE ACQUISITION CORP.

* Transaction values YS Biopharma at pre-money equity value of $834 million * Certain investors ...

2022-09-30 04:01 2464

YishengBio Received Approvals From Philippines and UAE For Phase 2 / 3 Clinical Trials of PIKA Recombinant COVID-19 vaccine

BEIJING, Sept. 8, 2022 /PRNewswire/ -- YishengBio Co., Ltd., ("YishengBio"), a biopharmaceutical co...

2022-09-08 21:33 2358

YishengBio Announces PIKA recombinant COVID-19 vaccine received Phase I clinical trial IND clearance from New Zealand

BEIJING, Aug. 9, 2021 /PRNewswire/ -- YishengBio Co., Ltd ("YishengBio") today announced that it re...

2021-08-09 21:00 2617

YishengBio Announces PIKA recombinant COVID-19 vaccine received Phase I clinical trial IND clearance from the UAE

BEIJING, July 19, 2021 /PRNewswire/ -- YishengBio Co., Ltd ("YishengBio") today announced that it h...

2021-07-19 09:00 2351